Psoriatic arthritis

Biologics and Targeted Therapies Revolutionize Psoriatic Arthritis Treatment: Market Analysis and Global Opportunity Assessment - ResearchAndMarkets.com

Retrieved on: 
수요일, 8월 2, 2023
Health, Other Health, Disease-modifying antirheumatic drug, Arthralgia, Psoriatic arthritis, Inflammation, Psoriasis, Route, Administration, Swelling, Nonsteroidal anti-inflammatory drug, OTC, Route of administration, Diagnosis, Skin, Geography, Pharmaceutical industry, Health insurance

The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • PsA is a chronic inflammatory arthritis that affects individuals with psoriasis, a skin condition characterized by red, scaly patches on the skin.
  • The psoriatic arthritis treatment market has witnessed growth due to increased awareness campaigns, educational initiatives, and advancements in diagnostic techniques, leading to early detection and diagnosis of PsA.
  • The psoriatic arthritis treatment market is segmented based on drug type, type, route of administration, and geography.

HSS Achieves Record 14th Consecutive National No. 1 Ranking in Orthopedics by U.S. News & World Report

Retrieved on: 
화요일, 8월 1, 2023
American Hospital Association, Human, Osteoarthritis, Psoriatic arthritis, US Youth Soccer National Championships, Evidence-based medicine, Centers for Medicare & Medicaid Services, Elective surgery, Culture, National Basketball Players Association, Hospital, Infection, Nursing, Scleroderma, MBA, Pickleball, Research, Lupus, American Animal Hospital Association, Doctor of Philosophy, Neck, The Internationale, Rheumatoid arthritis, Brooklyn Nets, Global Coalition Against Pneumonia, Pain, Medicare, Hospital for Special Surgery, Team physician, MD, Patient, Division, Medical Center, HSS, Joint, Health, New York Red Bulls, News, Safety, New York Road Runners, Health care, Rheumatology, U.S. News & World Report, New York Mets

NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Hospital for Special Surgery (HSS), has been ranked the No. 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No. 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis. 

Key Points: 
  • 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No.
  • 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis.
  • HSS maintains the lowest readmission rates for orthopedics in the nation, and among the lowest rates for infections and complications.
  • * Copyright © 2023 U.S. News & World Report, L.P. Data reprinted with permission from U.S. News.

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts  

Retrieved on: 
화요일, 7월 25, 2023
ACR, Psoriasis Area and Severity Index, Disease, Arm, Inflammation, Psoriatic arthritis, Capital market, Enthesitis, Clinical trial, Adalimumab, American College of Rheumatology, Hope, ARGO, Antibody, IL-17A, Doctor of Philosophy, Psoriasis, HS, Hidradenitis suppurativa, Patient, Physician, CEST, Webcast, Joint, PASI, MIRA, R, American College, Moonlake, FDA, Conference, Skin, Safety, Pharmaceutical industry, Cryptocurrency, Vaccine

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.

Key Points: 
  • MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.
  • Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “ARGO is MoonLake’s second trial to have achieved faster completion of recruitment and randomization than expected.
  • Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs.
  • The trial also includes adalimumab, the current standard of care for PsA, as an active reference arm.

EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar

Retrieved on: 
월요일, 7월 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Psoriasis Area and Severity Index, Intas Pharmaceuticals, Psoriatic arthritis, Partnership, CET, Ustekinumab, CSO, IQVIA, Dong Jiahong, Meiji, Marketing, Ulcerative colitis, Psoriasis, EMA, European Medicines Agency, Patient, PASI, Marketing Authorisation Application, MAA, Donga, III, MMA, Pharmaceutical industry, EU, Accord

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).

Key Points: 
  • Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
  • Accord , a wholly owned subsidiary of Intas Pharmaceuticals Ltd, submitted the MAA to EMA on June 23rd, and the EMA accepted the MMA submission on July 14th in CET.
  • The MAA submission is based on the results of an extensive analytical similarity assessment of DMB-3115 with that US and EU-sourced STELARA using current ‘state-of-the-art’ methods.
  • The MAA submission also comprised the results from the phase III multi-regional clinical trials in patients with plaque psoriasis (NCT04785326).

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Retrieved on: 
토요일, 7월 1, 2023
Crohn's & Colitis Foundation, National Psoriasis Foundation, Psoriatic arthritis, Interchangeability, Arthritis Foundation, Food and Drug Administration, Dermatology, Quality of life, American Academy, Colitis, Psoriasis, Crohn's disease, Boehringer Ingelheim, Patient, Risk, Phase, FDA, Health, Safety, Food, Management of Crohn's disease, Rheumatoid arthritis, Disease, Generic drug, Pharmaceutical industry, Adalimumab

Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Key Points: 
  • Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.
  • "Cyltezo is the first and only FDA-approved Interchangeable biosimilar to Humira® that is available to the millions of people in the U.S. living with certain chronic inflammatory diseases," said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim.
  • An Interchangeable biosimilar must first meet the high FDA standards of a biosimilar.
  • "For many people living with plaque psoriasis or psoriatic arthritis, finding effective relief from symptoms can be a daily struggle.

Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar

Retrieved on: 
금요일, 6월 16, 2023
Biotechnology, Pharmaceutical, Health, Contraindication, Bevacizumab, Partnership, Radiation, Marketing, European Medicines Agency, Methotrexate, PUVA, Ulcerative colitis, Psoriasis, EMA, Psoriatic arthritis, Patient, National Medical Products Administration, Ciclosporin, Biosimilar, FDA, Ustekinumab, NMPA, Pharmaceutical industry

Bio-Thera and Biomm’s partnership was initiated around a licensing and supply agreement for Biomm to distribute and market BAT1706, a bevacizumab biosimilar, in Brazil.

Key Points: 
  • Bio-Thera and Biomm’s partnership was initiated around a licensing and supply agreement for Biomm to distribute and market BAT1706, a bevacizumab biosimilar, in Brazil.
  • This partnership will leverage Biomm’s strong local presence, sales and marketing capabilities in Brazil.
  • “Bio-Thera is pleased to expand our partnership with Biomm to commercialize our ustekinumab biosimilar program in Brazil”, said Dr. Shengfeng Li, CEO of Bio-Thera.
  • “By expanding our partnership with Biomm, Bio-Thera is doubling its commitment to providing Brazilian patients with increased access to important biotherapeutics at affordable prices.”

AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

Retrieved on: 
목요일, 6월 15, 2023
2022–2023 monkeypox outbreak, Graft-versus-host disease, GVHD, NOAEL, Therapy, Federation of Clinical Immunology Societies, CD3, ICE, TT, Survival, Psoriasis, Inflammation, ELISA, P-selectin, DTH, Psoriatic arthritis, Patient, Ulcerative colitis, Tetanus, SAN, Toxicology, Mouse, NHP, Surface plasmon resonance, Research, Skin, Safety, Pharmaceutical industry, Vaccine

ALTB-268 is engineered to be a tetravalent version of its predecessor ALTB-168 and has a similar mechanism of action.

Key Points: 
  • ALTB-268 is engineered to be a tetravalent version of its predecessor ALTB-168 and has a similar mechanism of action.
  • ALTB-268, a tetravalent version of ALTB-168 demonstrated greater than 10-fold higher potency in in vitro T cell activation inhibition assays compared to ALTB-168.
  • The preclinical data will highlight a new role for PSGL-1 as a novel immune checkpoint regulator that modulates T cell homeostasis.
  • ALTB-168 has been clinically validated for safety, tolerability, and efficacy in treating inflammatory diseases including Psoriasis, Psoriatic Arthritis, Ulcerative Colitis and acute GVHD.

ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
목요일, 6월 15, 2023
Acceleration, Exercise, TED, SLRN, IPO, POC, IPR, D, Abscess, Enthesitis, Public, Quality of life, American Academy, Research, Doctor of Philosophy, Connective tissue, Graves' ophthalmopathy, Hidradenitis suppurativa, Psoriatic arthritis, Acquisition, MD, AAD, Patient, American Academy of Dermatology, LOS, Data monitoring committee, Hives, Neuro-ophthalmology, III, DMC, Disease, Autoimmunity, Inflammation, Life insurance, Pharmaceutical industry, HS

With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.

Key Points: 
  • With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.
  • Part B of the Phase 2b/3 trial completed enrollment early and top-line results are now anticipated in Q3 2023.
  • Net Loss: Net loss totaled $176.5 million for the first quarter of 2023, compared to $16.1 million for the first quarter of 2022.
  • This includes the one-time $123.1 million IPR&D charge and $10.0 million license payment, both related to the acquisition of ValenzaBio.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
월요일, 6월 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Confer

Retrieved on: 
수요일, 5월 31, 2023
Cystic fibrosis, Part, ECFC, Psoriatic arthritis, Patient, NESS, Poster, NYSE, Conference, Pharmaceutical industry

CAMBRIDGE, Mass.

Key Points: 
  • CAMBRIDGE, Mass.
  • and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference (ECFC), which is being held June 7-10th, 2023, in Vienna, Austria.
  • The Phase 1b/2a data will also be presented as a poster at the conference; posters will be located in Foyers E and F on Level 0.
  • Details of the oral presentation are as follows:
    The poster will also be made available on the publications section of the BiomX website on Friday, June 9th at 17:00 CEST.